Gain Therapeutics (GANX) Competitors

$1.78 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$1.78 -0.01 (-0.28%)

As of 05/22/2026 07:24 PM Eastern

GANX vs. ELDN, NVCT, PRLD, AKBA, and CGEN

Should you buy Gain Therapeutics stock or one of its competitors? MarketBeat compares Gain Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gain Therapeutics include Eledon Pharmaceuticals (ELDN), Nuvectis Pharma (NVCT), Prelude Therapeutics (PRLD), Akebia Therapeutics (AKBA), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry.

How does Gain Therapeutics compare to Eledon Pharmaceuticals?

Gain Therapeutics (NASDAQ:GANX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Gain Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,518.34	-$20.16M	-$0.58	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Eledon Pharmaceuticals' return on equity of -116.97% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

In the previous week, Eledon Pharmaceuticals had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 2 mentions for Eledon Pharmaceuticals and 0 mentions for Gain Therapeutics. Gain Therapeutics' average media sentiment score of 0.00 beat Eledon Pharmaceuticals' score of -0.54 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Gain Therapeutics	Neutral
Eledon Pharmaceuticals	Negative

Gain Therapeutics currently has a consensus target price of $8.50, suggesting a potential upside of 377.53%. Eledon Pharmaceuticals has a consensus target price of $9.67, suggesting a potential upside of 148.50%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Gain Therapeutics is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Gain Therapeutics has a beta of 0.15, indicating that its share price is 85% less volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

Summary

Gain Therapeutics beats Eledon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Gain Therapeutics compare to Nuvectis Pharma?

Gain Therapeutics (NASDAQ:GANX) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Gain Therapeutics has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,518.34	-$20.16M	-$0.58	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

Gain Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 377.53%. Nuvectis Pharma has a consensus price target of $10.00, suggesting a potential downside of 3.38%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Gain Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Nuvectis Pharma's return on equity of -161.00% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Nuvectis Pharma	N/A	-161.00%	-98.88%

In the previous week, Nuvectis Pharma's average media sentiment score of 1.00 beat Gain Therapeutics' score of 0.00 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Gain Therapeutics	Neutral
Nuvectis Pharma	Positive

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 30.5% of Nuvectis Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Gain Therapeutics has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.11, suggesting that its stock price is 111% less volatile than the broader market.

Summary

Gain Therapeutics beats Nuvectis Pharma on 8 of the 13 factors compared between the two stocks.

How does Gain Therapeutics compare to Prelude Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

Gain Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 377.53%. Prelude Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 79.55%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Gain Therapeutics is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Gain Therapeutics' average media sentiment score of 0.00 equaled Prelude Therapeutics'average media sentiment score.

Company	Overall Sentiment
Gain Therapeutics	Neutral
Prelude Therapeutics	Neutral

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Gain Therapeutics has higher earnings, but lower revenue than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,518.34	-$20.16M	-$0.58	N/A
Prelude Therapeutics	$12.14M	22.16	-$99.50M	-$1.00	N/A

Prelude Therapeutics' return on equity of -118.24% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Prelude Therapeutics	N/A	-118.24%	-66.12%

Gain Therapeutics has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the broader market.

Summary

Gain Therapeutics beats Prelude Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Gain Therapeutics compare to Akebia Therapeutics?

Akebia Therapeutics (NASDAQ:AKBA) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Akebia Therapeutics has higher revenue and earnings than Gain Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Gain Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.16	-$5.34M	-$0.08	N/A
Gain Therapeutics	$50K	1,518.34	-$20.16M	-$0.58	N/A

Akebia Therapeutics has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.15, suggesting that its stock price is 85% less volatile than the broader market.

Akebia Therapeutics currently has a consensus price target of $4.67, indicating a potential upside of 357.52%. Gain Therapeutics has a consensus price target of $8.50, indicating a potential upside of 377.53%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Gain Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Akebia Therapeutics' return on equity of -62.72% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-8.83%	-62.72%	-5.66%
Gain Therapeutics	N/A	-201.44%	-136.24%

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Akebia Therapeutics had 1 more articles in the media than Gain Therapeutics. MarketBeat recorded 1 mentions for Akebia Therapeutics and 0 mentions for Gain Therapeutics. Akebia Therapeutics' average media sentiment score of 0.37 beat Gain Therapeutics' score of 0.00 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Akebia Therapeutics	Neutral
Gain Therapeutics	Neutral

Summary

Akebia Therapeutics beats Gain Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Gain Therapeutics compare to Compugen?

Compugen (NASDAQ:CGEN) and Gain Therapeutics (NASDAQ:GANX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

In the previous week, Compugen had 16 more articles in the media than Gain Therapeutics. MarketBeat recorded 16 mentions for Compugen and 0 mentions for Gain Therapeutics. Compugen's average media sentiment score of 0.14 beat Gain Therapeutics' score of 0.00 indicating that Compugen is being referred to more favorably in the media.

Company	Overall Sentiment
Compugen	Neutral
Gain Therapeutics	Neutral

Compugen currently has a consensus target price of $5.00, indicating a potential upside of 78.57%. Gain Therapeutics has a consensus target price of $8.50, indicating a potential upside of 377.53%. Given Gain Therapeutics' higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Compugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

12.2% of Compugen shares are owned by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 4.2% of Gain Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Compugen has higher revenue and earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.64	$35.34M	$0.37	7.57
Gain Therapeutics	$50K	1,518.34	-$20.16M	-$0.58	N/A

Compugen has a beta of 2.79, meaning that its stock price is 179% more volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market.

Compugen has a net margin of 47.97% compared to Gain Therapeutics' net margin of 0.00%. Compugen's return on equity of 47.72% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.97%	47.72%	27.51%
Gain Therapeutics	N/A	-201.44%	-136.24%

Summary

Compugen beats Gain Therapeutics on 14 of the 17 factors compared between the two stocks.

Get Gain Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GANX vs. The Competition

Export

Metric	Gain Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$75.92M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-3.07	17.79	21.00	25.66
Price / Sales	1,518.34	336.21	562.18	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	5.39	5.86	10.41	7.14
Net Income	-$20.16M	$74.99M	$3.57B	$335.98M
7 Day Performance	12.66%	3.11%	6.40%	4.11%
1 Month Performance	-9.64%	-3.05%	3.54%	2.52%
1 Year Performance	-1.11%	34.38%	34.14%	35.04%

Gain Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GANX Gain Therapeutics	1.321 of 5 stars	$1.78 flat	$8.50 +377.5%	-1.1%	$75.92M	$50K	N/A	20
ELDN Eledon Pharmaceuticals	1.8839 of 5 stars	$3.58 flat	$9.67 +170.0%	+27.5%	$276.33M	N/A	N/A	10
NVCT Nuvectis Pharma	0.8294 of 5 stars	$10.30 -1.0%	$10.00 -2.9%	+5.3%	$275.87M	N/A	N/A	8	Positive News Gap Up
PRLD Prelude Therapeutics	4.0696 of 5 stars	$4.27 -1.6%	$7.67 +79.5%	+381.8%	$273.43M	$12.14M	N/A	120	Gap Up
AKBA Akebia Therapeutics	2.4457 of 5 stars	$0.90 -11.4%	$4.67 +421.4%	-64.3%	$270.94M	$236.20M	N/A	430	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GANX) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gain Therapeutics (GANX) Competitors

GANX vs. ELDN, NVCT, PRLD, AKBA, and CGEN

How does Gain Therapeutics compare to Eledon Pharmaceuticals?

Summary

How does Gain Therapeutics compare to Nuvectis Pharma?

Summary

How does Gain Therapeutics compare to Prelude Therapeutics?

Summary

How does Gain Therapeutics compare to Akebia Therapeutics?

Summary

How does Gain Therapeutics compare to Compugen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gain Therapeutics (GANX) Competitors

GANX vs. ELDN, NVCT, PRLD, AKBA, and CGEN

How does Gain Therapeutics compare to Eledon Pharmaceuticals?

Which has higher earnings & valuation, GANX or ELDN?

Do insiders & institutionals hold more shares of GANX or ELDN?

Is GANX or ELDN more profitable?

Does the media prefer GANX or ELDN?

Do analysts recommend GANX or ELDN?

Which has more risk and volatility, GANX or ELDN?

Summary

How does Gain Therapeutics compare to Nuvectis Pharma?

Which has higher valuation and earnings, GANX or NVCT?

Do analysts rate GANX or NVCT?

Is GANX or NVCT more profitable?

Does the media prefer GANX or NVCT?

Do insiders and institutionals hold more shares of GANX or NVCT?

Which has more risk and volatility, GANX or NVCT?

Summary

How does Gain Therapeutics compare to Prelude Therapeutics?

Do analysts rate GANX or PRLD?

Does the media favor GANX or PRLD?

Do insiders and institutionals hold more shares of GANX or PRLD?

Which has better earnings & valuation, GANX or PRLD?

Is GANX or PRLD more profitable?

Which has more risk and volatility, GANX or PRLD?

Summary

How does Gain Therapeutics compare to Akebia Therapeutics?

Which has better earnings and valuation, AKBA or GANX?

Which has more risk & volatility, AKBA or GANX?

Do analysts recommend AKBA or GANX?

Is AKBA or GANX more profitable?

Do insiders and institutionals have more ownership in AKBA or GANX?

Does the media prefer AKBA or GANX?

Summary

How does Gain Therapeutics compare to Compugen?

Does the media refer more to CGEN or GANX?

Do analysts prefer CGEN or GANX?

Do insiders & institutionals believe in CGEN or GANX?

Which has stronger earnings & valuation, CGEN or GANX?

Which has more volatility & risk, CGEN or GANX?

Is CGEN or GANX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX vs. The Competition

Gain Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools